The purpose of the study is to evaluate the long‑term outcomes and safety of repeated adjuvant (additional) treatment with rituximab in this condition. Participants receive two infusions several weeks apart and are then followed for several months with regular clinic visits to check how they feel and to monitor any side effects.

During the follow‑up, doctors use simple rating scales such as the Clinical Global Impression – Improvement, which measures how much a person’s symptoms have gotten better, and the Clinical Global Impression – Severity, which rates how serious the illness is. Patients also complete short questionnaires about their overall health, daily functioning, and any changes in blood tests that may show immune system activity. Family members may be asked to give their view of any improvement as well.

Participants will take the study drug by mouth every day for several months, with regular visits to check for any side effects and to answer simple questionnaires. Researchers will monitor for any new health problems, serious problems, and specific symptoms related to the study drugs. They will also use a few rating tools to watch for movement‑related side effects and to assess thoughts of self‑harm, using the C-SSRS questionnaire and movement scales called the SAS, BARS, and AIMS. The study ends after the treatment period and a short follow‑up to confirm the safety findings.

The purpose of this study is to see if NBI-1117568 works better than placebo at improving the behavioral and psychological symptoms of schizophrenia in adults. The study will look at whether the medication can help reduce symptoms and improve the overall condition of people who are experiencing a sudden worsening of their schizophrenia symptoms that requires them to stay in the hospital. The study will also check how safe the medication is and whether people can tolerate it well.

People taking part in this study will be adults with schizophrenia who are currently in the hospital because their symptoms have gotten worse recently. The study will last for 5 weeks, during which time participants will take either NBI-1117568 or placebo capsules. Throughout the study, doctors will measure changes in symptoms using rating scales to see how well the treatment is working compared to placebo.

The research involves comparing the effects of the active medication against the placebo to see how it influences both positive and negative symptoms. Positive symptoms refer to behaviors that are added to a person’s experience, such as delusions, while negative symptoms involve a loss of normal functions, such as a lack of emotion or motivation. During the study, doctors will monitor various aspects of health, including physical signs, heart activity through an ECG, and changes in movement or behavior.

Participants in this research will be assigned to receive either KarXT or a placebo. This is a randomized study, meaning participants are placed into groups by chance, and it is double-blind, which means neither the participants nor the researchers know which treatment is being given. During the study, the way the medication affects the symptoms of the condition will be observed over a period of several weeks.

The study is a randomized and double-blind trial, meaning that participants are assigned to groups by chance and neither the individuals nor the medical staff know which specific treatment is being given during the study period. This design helps ensure that the results are based on the actual effects of the medication. Researchers will observe how the medication affects the behavioral and psychological symptoms of the condition over time.

People taking part in this study will have schizophrenia with symptoms that have gotten worse and will either be in the hospital or need to be in the hospital because of their condition. Their symptoms must have started getting worse within the past two months. Before joining the study, they must have been treated with other antipsychotic medications that worked for them in the past year. During the study, participants will be randomly assigned to receive either the brexpiprazole medication or placebo, and neither they nor their doctors will know which one they are getting. The treatment will be given by mouth as tablets.

The study will measure how much the symptoms change from the beginning of the study to week six. Doctors will use a standard rating scale to measure the symptoms of schizophrenia throughout the study period. The medication will be given once a week, and the study will track how well it works and whether it is safe for people with acute schizophrenia.

The purpose of this study is to evaluate the long-term safety of NBI-1117568 in adults with schizophrenia. The study will look at what unwanted effects or side effects may occur when people take this medication over an extended period of time. This is an open-label study, which means that both the participants and the doctors will know that everyone is receiving the actual medication rather than placebo.

During the study, participants will receive NBI-1117568 for up to 156 weeks, which is about three years. Some participants may be coming directly from a previous study where they were already taking this medication. Throughout the treatment period, doctors will monitor participants regularly to check for any side effects or health changes that may occur while taking the medication. The study will track and record any unwanted effects that participants experience during the treatment period.

The purpose of this research is to determine if evenamide, when added to existing antipsychotic medication, can help improve schizophrenia symptoms. The study will compare two different doses of evenamide (15 mg and 30 mg taken twice daily) to a placebo. Participants will continue taking their current antipsychotic medication throughout the study.

The study will last for 52 weeks, with the main evaluation of the medication’s effectiveness occurring after 12 weeks of treatment. During this time, participants will receive either evenamide capsules or placebo capsules to take twice daily along with their regular medication. The study will monitor both how well the medication works and any side effects that may occur.

The purpose of the study is to explore how GT-002 affects certain brain activities in people with schizophrenia. Participants will receive either GT-002, oxazepam, or a placebo and will undergo tests to measure changes in brain function and mood. These tests include monitoring brain waves using a method called EEG, which records electrical activity in the brain, and other assessments to understand how the treatment impacts thinking and attention.

The study will take place over a short period, and participants will be closely monitored for any side effects or changes in their condition. The goal is to gather information on the safety and effectiveness of GT-002 in improving cognitive function in people with schizophrenia, which could lead to better treatment options in the future.

The purpose of the study is to explore the relationship between brain inflammation and genetic factors in people with schizophrenia. The study will include both patients with schizophrenia and healthy volunteers. Participants will undergo PET scans to measure brain inflammation and may also have other types of scans, like MRI, to look at brain structure and connections. The study will also check for other health markers, such as cholesterol levels and blood sugar, to see how they relate to brain inflammation.

The study will take place over several years, with the goal of better understanding how genetic factors might influence brain inflammation in schizophrenia. This research could help in developing new ways to diagnose or treat the condition in the future.

Participants in the study will be randomly assigned to receive either melatonin, quetiapine, or a placebo. The treatment will be given in the form of film-coated tablets, which are taken orally. The study will last for a period of six months, during which the effects of the treatments on sleep and overall well-being will be monitored. The study aims to provide insights into which treatment might be more effective in managing insomnia in adolescents with psychiatric conditions.

Throughout the study, various aspects of the participants’ sleep and mental health will be assessed. This includes measuring the severity of insomnia using the Insomnia Severity Index, evaluating sleep quality, and assessing psychosocial functioning and subjective well-being. The study will also look at how the treatments affect rest-sleep-activity cycles and other physiological variables. The findings from this study could help improve treatment options for young people dealing with both psychiatric disorders and sleep difficulties.

Participants in the study will receive either tirzepatide or a placebo for a period of up to 26 weeks. The study will monitor changes in alcohol consumption, specifically looking at the number of heavy drinking days, which are defined as days with a high intake of alcohol. Additionally, the study will evaluate other factors such as alcohol cravings, overall alcohol consumption, and quality of life. The effects of tirzepatide on symptoms of schizophrenia and other health parameters will also be assessed.

The trial will involve regular assessments to track progress, including the use of questionnaires and tests to measure alcohol use and mental health. Some participants may also undergo additional evaluations, such as fMRI scans, to study brain activity related to alcohol cues. The goal is to determine if tirzepatide can provide a beneficial treatment option for individuals with both schizophrenia and alcohol use disorder.

The purpose of the study is to evaluate the safety and effectiveness of NaBen in reducing the symptoms of schizophrenia that persist despite treatment with clozapine. Participants in the study will receive either NaBen or a placebo, which looks like the medication but does not contain the active ingredient. The study will be conducted in two parts. In the first part, different doses of NaBen will be tested to find the most effective dose. In the second part, the best dose from the first part will be used to further assess its effectiveness compared to the placebo.

Participants will take the medication orally in the form of film-coated tablets for a period of up to eight weeks. Throughout the study, changes in symptoms will be monitored using various scales and assessments to determine the impact of the treatment. The goal is to find out if NaBen can provide additional benefits for those who have not responded well to other treatments for schizophrenia.

The purpose of the study is to use advanced techniques to identify biological markers that can predict how well a patient will respond to these treatments. Patients will receive either Aripiprazole or Paliperidone for a period of up to one year. The study will monitor changes in symptoms and overall health at three and twelve months to determine the effectiveness of the treatments. The study will also look at how long patients continue with their initial treatment and any side effects they may experience.

Throughout the study, various aspects of the patients’ health will be assessed, including changes in symptoms, quality of life, and any side effects. The study aims to provide a better understanding of how these medications work in treating schizophrenia and related conditions, ultimately helping to improve treatment strategies for these patients.

Participants in the study will receive either Vortioxetine or a standard treatment, which may include other medications such as Haloperidol, Ziprasidone, Aripiprazole, Olanzapine, Pimozide, Quetiapine, Chlorpromazine, Thioridazine, Risperidone, or Pregabalin. These medications are typically used to manage symptoms of schizophrenia and related disorders. The study will last for a period of up to 48 weeks, during which participants will take the medication orally, meaning by mouth, and their cognitive functions will be monitored and assessed at various points throughout the study.

The trial aims to determine if Vortioxetine can provide additional benefits in improving cognitive abilities compared to the usual treatments. Participants will be monitored for changes in their cognitive performance using a specific assessment tool designed for schizophrenia. This study is important for understanding how Vortioxetine might help people with schizophrenia improve their mental processes and overall quality of life.

The purpose of the study is to evaluate how effective and safe cariprazine is for treating adolescents with schizophrenia. Participants will be randomly assigned to receive either cariprazine or a placebo for a period of six weeks. During this time, the participants will take the medication orally, which means by mouth, in the form of hard capsules. The study will monitor changes in symptoms and any side effects that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the impact of the treatment. This includes monitoring vital signs, conducting physical examinations, and evaluating any changes in their condition. The study aims to provide valuable information on the use of cariprazine for treating schizophrenia in young people, helping to determine its potential benefits and risks.

The purpose of this research is to evaluate the long-term safety and how well patients tolerate KarXT when it is used together with their regular antipsychotic medication. The medication comes in the form of capsules that are taken by mouth. Different doses of KarXT will be tested during the study, which will last for up to 52 weeks.

During the study, participants will continue taking their regular antipsychotic medication while also receiving KarXT. The healthcare team will monitor participants throughout the study period to track any side effects that may occur and assess how well patients tolerate the combination of medications. This is a continuation study for people who have completed a previous trial with KarXT.

Participants in the study will receive either the medication Tavegil Tabletten, which contains clemastine, or a placebo, which looks like the medication but does not contain any active ingredients. The treatment will be taken orally in the form of tablets. The study will last for about three months, during which participants will be monitored for changes in their cognitive abilities, such as memory and overall functioning. The goal is to observe any improvements in these areas from the start to the end of the study period.

Throughout the study, various assessments will be conducted to measure changes in cognitive performance and overall mental health. These assessments include tests like the Global Assessment of Functioning (GAF) and the n-back test, which evaluates working memory. The study will also look at other factors such as physical fitness, quality of life, and any side effects that may occur. The findings from this study could provide valuable insights into new ways to support individuals with schizophrenia in managing cognitive challenges.

Participants in the study will receive Rituximab through an infusion, which means the medication is delivered directly into the bloodstream via a vein. The study will compare the effects of Rituximab with a placebo to see if there is a significant difference in the improvement of symptoms. The trial will last for several weeks, during which participants will be monitored for changes in their condition. The main goal is to see if there is at least a 30% improvement in symptoms as measured by a standard scale used to assess schizophrenia.

Throughout the study, various assessments will be conducted to evaluate the participants’ mental health and overall well-being. These assessments include interviews and questionnaires that measure the severity of symptoms and the impact on daily life. The study aims to provide valuable insights into whether Rituximab can be an effective treatment option for individuals with schizophrenia, potentially leading to better management of the condition in the future.

Participants in the study will receive either cannabidiol or a placebo in the form of hard capsules. These capsules are taken orally, meaning they are swallowed. The study will be conducted over a period of time, during which participants will continue their usual antipsychotic treatment. The goal is to see if adding cannabidiol can help improve recovery in individuals with early-phase schizophrenia. The study will monitor various aspects of participants’ health and well-being, including their mental health symptoms, social and occupational functioning, and overall quality of life.

Throughout the study, researchers will also keep track of any changes in participants’ mood, cognitive abilities, and any side effects they may experience. This will help determine the safety and tolerability of cannabidiol as an additional treatment. The study aims to provide valuable insights into whether cannabidiol can be a beneficial add-on therapy for people with schizophrenia, potentially enhancing their recovery and quality of life.

Participants in the study will be randomly assigned to receive either Valbenazine or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of 10 weeks, during which participants will take the medication in capsule form by mouth.

The main goal of the study is to observe any changes in the symptoms of schizophrenia over the course of the treatment. Researchers will monitor participants’ progress and gather data to determine the safety and effectiveness of Valbenazine as an additional treatment option for schizophrenia. The study will also assess how well participants tolerate the medication, looking at any side effects or other issues that may arise during the trial period.

The study is based on a specific genetic variation known as the rs4680 polymorphism of the COMT enzyme gene. This genetic factor may influence how well tolcapone works in improving cognitive abilities in patients. Participants in the study will take Tasmar in the form of film-coated tablets, and the medication will be administered orally. The trial will compare the effects of tolcapone with a placebo to determine its effectiveness.

Throughout the study, participants will undergo various assessments to measure changes in their cognitive performance and brain activity. These assessments may include tests like the DPX cognitive test and brain imaging techniques such as functional MRI (fMRI). The study will also evaluate the participants’ overall well-being and any changes in their symptoms using clinical scales. The trial is designed to last for a specific period, during which participants will be closely monitored to ensure their safety and to gather comprehensive data on the effects of tolcapone.

The purpose of the study is to evaluate whether adding oxytocin to the usual psychosocial treatment can improve social skills in individuals with schizophrenia spectrum disorders. Participants in the study will receive either the oxytocin nasal spray or the placebo, in addition to their regular psychosocial treatment. The study will last for a period of 12 weeks, during which the effects of the treatment on social skills and overall functioning will be monitored.

Throughout the study, researchers will assess changes in personal and social performance, as well as other aspects such as quality of life and cognitive function. The goal is to determine if oxytocin can be a beneficial addition to existing treatments for improving social interactions and quality of life for those living with schizophrenia spectrum disorders.

The purpose of the study is to evaluate the safety and effectiveness of RL-007 in improving cognitive performance in participants diagnosed with schizophrenia. Participants will be randomly assigned to receive either RL-007 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for a period of six weeks, during which participants will take the medication orally and attend regular study visits for assessments.

Throughout the study, participants will undergo various tests to measure changes in their cognitive abilities, such as memory and attention, as well as overall health checks, including vital signs and laboratory tests. The study aims to provide valuable information on whether RL-007 can help improve cognitive function in people with schizophrenia, potentially leading to better treatment options in the future.

The purpose of this research is to determine if KarXT, when added to current schizophrenia treatment, can help reduce symptoms better than placebo. During the study, participants will continue taking their regular schizophrenia medication while also receiving either KarXT capsules or placebo capsules. The medication will be taken by mouth.

The study will last 6 weeks, during which the effectiveness of KarXT will be measured by tracking changes in schizophrenia symptoms. Throughout the study, participants will need to visit the clinic regularly for check-ups. The medication dose may be adjusted during the study period, with the highest possible daily dose being 310 milligrams.

The purpose of this study is to gather additional safety information about Iclepertin in patients who have cognitive impairment due to schizophrenia. Cognitive impairment refers to difficulties with thinking, memory, and concentration, which can be a part of schizophrenia. Participants in this study will continue to take Iclepertin daily for up to 12 months. The study will monitor the occurrence of any new or worsening side effects, known as treatment emergent adverse events, throughout the trial.

In addition to monitoring side effects, the study will also assess changes in the severity of the participants’ condition using a measure called the Clinical Global Impressions – Severity (CGI-S) scale. This scale helps to evaluate how severe the symptoms are at the start of the study compared to the end. The study aims to provide valuable information on the long-term safety of Iclepertin for people living with schizophrenia.

The purpose of this study is to evaluate the long-term safety of Cariprazine in young patients with schizophrenia. Participants in the study will take the medication orally, meaning they will swallow the capsules. The study will last for up to two years, during which time the participants will be monitored regularly to assess their health and any side effects they may experience. This monitoring will include various health checks, such as blood tests and physical examinations, to ensure the safety of the participants.

Throughout the study, participants will be closely observed for any adverse events or changes in their health. The study aims to gather information on how the medication affects the participants’ overall well-being and whether it helps in managing the symptoms of schizophrenia. By the end of the study, researchers hope to have a better understanding of the long-term effects of Cariprazine in treating adolescents with schizophrenia, which could contribute to improved treatment options for this condition in the future.

The purpose of the study is to compare the effectiveness of this intensified treatment with the usual treatment in reducing symptoms of these conditions. Participants will receive either the intensified treatment or the usual treatment for six weeks. The study will monitor changes in symptom severity using a tool called the Positive and Negative Syndrome Scale (PANSS), which helps measure the severity of symptoms in these disorders. The study will also look at other aspects such as anxiety, depression, quality of life, and any side effects experienced during the treatment period.

Participants will be observed over a six-week period, during which they will have regular visits to assess their progress. The study aims to provide insights into whether an intensified treatment approach can offer better outcomes for individuals who have not responded well to their initial treatment. This research could help improve treatment strategies for people living with schizophrenia and related disorders.

Participants in the study will be patients diagnosed with schizophrenia or schizoaffective disorders, which are specific types of psychosis. The study will look at the frequency of certain gene variations, known as polymorphisms, in genes like CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4. These genes may influence how patients respond to olanzapine. The study will also assess other factors such as the rate of treatment response, which is measured by a reduction in symptoms, and any side effects experienced during the treatment.

Throughout the study, participants will be monitored for changes in their symptoms and any side effects from the medication. The study will also track how long it takes for participants to show a response to the treatment. This research aims to provide a better understanding of how olanzapine works in treating psychosis and how individual genetic differences can affect treatment outcomes.

Participants in the study will receive either Valbenazine or a placebo, which is a substance with no active medication. The study will last for a period of 10 weeks, during which participants will take the medication in capsule form by mouth. The goal is to observe any changes in the symptoms of schizophrenia, as well as overall health and social functioning, over this time.

The study is designed to provide valuable information on whether adding Valbenazine to the treatment plan can help improve the symptoms of schizophrenia in those who are already on a stable regimen of antipsychotic medication. This research could potentially lead to better treatment options for individuals living with this condition.

The purpose of the study is to see if an early-intensified treatment can improve symptoms more effectively than the standard approach. Participants will be randomly assigned to receive either the intensified treatment or the usual treatment. The study will last for four to six weeks, depending on the specific condition being treated. During this time, participants will receive their assigned treatment and have their symptoms monitored to assess any changes in severity.

This trial is designed for individuals who have experienced a first-time failure with their initial treatment for schizophrenia, major depressive disorder, or bipolar depression. The goal is to determine if a more aggressive treatment approach can lead to better outcomes for these patients. Participants will be closely monitored throughout the study to ensure their safety and to evaluate the effectiveness of the treatments being tested.

The purpose of the study is to evaluate how effective and safe SEP-363856 is for treating acute psychotic symptoms in people with schizophrenia. Participants in the study will be randomly assigned to receive either a fixed dose of SEP-363856 or a placebo. The study will begin with a double-blind phase, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This phase will last for six weeks. After this, there will be an open-label extension phase where all participants will have the opportunity to receive SEP-363856.

Throughout the study, participants will be monitored to assess changes in their symptoms using a tool called the Positive and Negative Syndrome Scale (PANSS), which measures the severity of schizophrenia symptoms. The study aims to determine if SEP-363856 can help reduce these symptoms and improve the overall condition of those affected by schizophrenia.

The purpose of the study is to evaluate how well vafidemstat works in reducing negative symptoms and improving cognitive function in people with schizophrenia. Negative symptoms can include things like lack of motivation, reduced emotional expression, and social withdrawal, while cognitive impairment refers to difficulties with memory, attention, and problem-solving. Participants in the study will be randomly assigned to receive either vafidemstat or the placebo, and neither the participants nor the researchers will know who is receiving which treatment.

The study will last for 24 weeks, during which participants will take the capsules regularly and attend scheduled visits with the research team. These visits will help monitor the participants’ progress and any changes in their symptoms. The study aims to provide valuable information about the potential benefits of vafidemstat for individuals living with schizophrenia.

The purpose of the study is to explore certain biological markers, known as biomarkers, that might predict how well a person with schizophrenia will respond to clozapine. Participants in the study will continue their stable antipsychotic treatment and will be monitored over a period of time to observe any changes or improvements in their symptoms. The study aims to understand the role of these biomarkers in the treatment process.

Throughout the study, researchers will also examine the permeability of the blood-brain barrier, which is a protective layer that controls what substances can enter the brain from the bloodstream. They will look at inflammatory substances in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord, to gather more information about the body’s response to clozapine. The study is expected to continue until the end of 2029.

During the study, participants will begin treatment with cariprazine and will be monitored over a period of 28 weeks. The study will observe changes in cognitive abilities, which are the mental processes involved in gaining knowledge and understanding, such as thinking, knowing, remembering, and judging. Participants will not be hospitalized due to worsening of psychosis and will not have any changes in their psychopharmacological treatment for at least 8 weeks prior to the study. The study aims to provide insights into how cariprazine may help improve cognitive functioning in individuals with schizophrenia.

Throughout the study, various assessments will be conducted to evaluate the effects of cariprazine. These assessments will include tests and measures that help understand changes in cognitive abilities and overall mental health. The study will also involve the use of imaging techniques like fMRI (functional Magnetic Resonance Imaging) to observe brain activity. The results of this study may contribute to better understanding and management of cognitive symptoms in schizophrenia, potentially leading to improved treatment options for patients.